Highlights BerGenBio ASA

Equities

BGBIO

NO0010650013

Market Closed - Oslo Bors Other stock markets 08:15:00 08/05/2024 pm IST			5-day change	1st Jan Change
0.137 ^NOK	0.00%		-5.52%	-50.72%

20/03	Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	CI
14/02	BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	21/03	CI
BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023	14/02	CI
BerGenBio ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/02	CI
BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections	07/02	CI
BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients	16/12	CI
BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting	11/12	CI
BerGenBio ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Bergenbio Announces Data from Biomarker Analyses in 2L Nsclc	06/11	CI
BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer	23/23/23	CI
BerGenBio ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23/23/23	CI
BerGenBio ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	22/23/22	CI
BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO	05/23/05	CI
BerGenBio ASA Presents Data on STK11 Loss of Function and AXL Activation at AACR	18/23/18	CI
BerGenBio ASA Announces First Patient Dosed In Phase 1B/2A Trial Evaluating Bemcentinib In 1St Line Non-Small Cell Lung Cancer With Stk11 Mutations	09/23/09	CI
BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2022	16/23/16	CI
BerGenBio ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	16/23/16	CI
BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients	15/23/15	CI
BerGenBio ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations	11/22/11	CI
BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients	27/22/27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BerGenBio ASA

Equities

BGBIO

NO0010650013

Highlights

Filters